GlobeNewswire by notified

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Share

Company Announcement

COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will, with the exception of deferred annual cash bonus, be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,013.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. 

The exercise price for each warrant is DKK 2,013. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 652.81.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:          
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Company Announcement no. 09
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

KALLELSE TILL ÅRSSTÄMMA I CLEAN MOTION AB15.4.2024 16:46:16 CEST | Pressemelding

Aktieägarna i Clean Motion AB, 556788-1825, kallas härmed till årsstämma onsdagen den 15 maj 2024 kl 17.00 i Tingshuset, på Göteborgsvägen 24 i Lerum. Rätt till deltagande och anmälan: Aktieägare som önskar att delta i årsstämman, ska dels vara införd i den av Euroclear Sweden AB förda aktieboken den 6 maj 2024 och dels anmäla sitt deltagande till bolaget under adress: Clean Motion AB, ”Årsstämma” Strandvägen 12, SE-443 32 Lerum, eller via e-post till info@cleanmotion.se senast den 9 maj 2024. Vid anmälan ska namn, personnummer/organisationsnummer, adress, telefonnummer (dagtid) samt aktieinnehav anges. Om aktieägaren avser att medföra biträde till årsstämman, ska antal (högst två) och namn på biträde anmälas hos bolaget enligt ovan. Ombud Om aktieägaren avser att låta sig företrädas genom ombud ska skriftlig, daterad fullmakt, utfärdas för ombudet. Fullmaktsformulär finns tillgängligt på www.cleanmotion.se. Fullmakten får inte vara utfärdad tidigare än ett år före dagen för årsstämman

Aðalfundur Ísfélags hf. 2024 - Frambjóðendur til stjórnar, dagskrá og endanlegar tillögur.15.4.2024 16:45:34 CEST | Press release

Fundurinn er haldinn rafrænt og á Tangagötu 1 Vestmannaeyjum þann 17. apríl 2024 kl. 16:00. Meðfylgjandi eru upplýsingar um frambjóðendur til stjórnar félagsins sem eru í kjöri á aðalfundinum 17. apríl 2024. Framboðsfrestur er útrunninn. Samkvæmt samþykktum félagsins kýs aðalfundur allt að sjö menn í stjórn. Fimm einstaklingar eru í kjöri til aðalstjórnar og er því sjálfkjörið í stjórn. Í kjöri til stjórnar eru: Einar SigurðssonGuðbjörg MatthíasdóttirGunnar SigvaldasonSteinunn H. MarteinsdóttirSigríður Vala Halldórsdóttir Engar breytingar eru á fyrirliggjandi tillögum fyrir fundinn eða áður birtri dagskrá. Tillögur eru meðfylgjandi. Hluthafar eða umboðsmenn hluthafa sem hafa hug á því að sækja fundinn, hvort sem er rafrænt eða á staðnum, þurfa að skrá sig á https://www.lumiconnect.com/meeting/isfelagagm2024 eigi síðar en kl. 16:00 þann 16. apríl 2024, eða degi fyrir fundardag. Með innskráningu þarf að fylgja mynd af skilríkjum og umboð, ef við á. Mikilvægt er að skrá sig á fundinn þó m

BW Energy: Mandatory Notifications of Trade and Disclosure of Shareholding15.4.2024 16:30:00 CEST | Press release

BW Energy: Mandatory Notifications of Trade and Disclosure of Shareholding Marco Beenen, Director of BW Energy Limited ("BWE"), sold 32,647 shares in BWE on April 12th at an average price of NOK 28.55 per share. Following this transaction, Mr. Beenen holds no shares in BW Energy Limited. For further information, please contact: ir@bwenergy.no About BW Energy: BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments. The Company has access to existing production facilities to reduce time to first oil and cashflow with lower investments than traditional offshore developments. The Company's assets are 73.5% of the producing Dussafu Marine licence offshore Gabon, 100% interest in the Golfinho and Camarupim fields, a 76.5% interest in the BM-ES-23 block in, a 95% interest in the Maromba field in Brazil and a 95% interest in the Kudu field in Namibia, all operated by BW Energy. Total net 2P+2C reser

Resume af ordinær generalforsamling15.4.2024 15:57:12 CEST | pressemeddelelse

Selskabsmeddelelse nr. 5 – 2024 København, den 15. april 2024 Resume af ordinær generalforsamling På NTR Holding A/S’ ordinære generalforsamling mandag den 15. april 2024 blev selskabets årsrapport for 2023 godkendt, forslaget om anvendelse af årets resultat, herunder at der ikke udbetales udbytte, godkendt, vederlagsrapporten for 2023 godkendt, vederlaget til bestyrelsen for regnskabsåret 2024 på DKK 200.000 til bestyrelsesformanden og DKK 100.000 til hvert af de øvrige bestyrelsesmedlemmer godkendt, direktion og bestyrelse meddelt decharge, bestyrelsen bemyndiget til i tiden indtil næste ordinære generalforsamling at lade selskabet erhverve egne aktier, idet selskabets samlede beholdning af egne aktier efter erhvervelsen ikke må overstige 10% af selskabskapitalen, bestyrelsens bemyndigelse til at forhøje selskabets B-aktiekapital jf. vedtægternes § 3a fornyet frem til 15. april 2029, vederlagspolitikken godkendt, Ole Steffensen, Anders Ørjan Jensen og Klaus Kjærulff genvalgt til best

HiddenA line styled icon from Orion Icon Library.Eye